2021 Annual Meeting | C87 - Child Neurology for Adult Neurology Residents

Date Wednesday 04/21/21

Time 04:00 PM - 05:00 PM EDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Megan A. Waldrop, MD, Jennifer A. Vermilion, MD

Moderator(s) Barry K. Vaught, MD, FAAN

Topic(s) Research Methodology, ��ɫ��, and History

Learning Objectives Upon completion, participants should be able to understand the basic types of gene therapy and the principles behind designing a gene therapy product, along with general outcomes of gene therapies in SMA and DMD.
Participants should also be able to recognize clinical characteristics of tics and tic disorders in children and recognize clinical characteristics of stereotypies in children and understand the differences between primary and secondary stereotypies.

CME Available 1.00 CME credit

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism, Medical Knowledge

Program Level Introductory

Program Tracks Advanced Practice Provider

Recommended Audience Resident, Advanced Practice Provider, Medical Student

Teaching Styles Case-based, Didactic

Program Materials Program Evaluations

Event Timeline
04:00 PM - 04:25 PM EDT	Speaker	Update on the Therapeutic Revolution in Neuromuscular Diseases Megan A. Waldrop, MD
04:25 PM - 04:50 PM EDT	Speaker	The Practical Approach to Tics and Stereotypy in Childhood Jennifer A. Vermilion, MD
04:50 PM - 05:00 PM EDT	Q&A	Live Q&A Megan A. Waldrop, MD, Jennifer A. Vermilion, MD

Faculty Disclosures
Megan A. Waldrop, MD	Dr. Waldrop has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sarepta Therapeutics. Dr. Waldrop has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis Gene Therapies.
Jennifer A. Vermilion, MD	The institution of Dr. Vermilion has received research support from Centers for Disease Control. The institution of Dr. Vermilion has received research support from Emalex Biosciences. The institution of Dr. Vermilion has received research support from Biomarin. The institution of Dr. Vermilion has received research support from Neurogene, Inc. Dr. Vermilion has received personal compensation in the range of $500-$4,999 for serving as a Invited Speaker with Tourette Association of America. Dr. Vermilion has received personal compensation in the range of $500-$4,999 for serving as a Invited Speaker with Centers for Disease Control and Prevention and American Academy of Pediatrics.
Barry K. Vaught, MD, FAAN	The institution of Dr. Vaught has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biohaven. The institution of Dr. Vaught has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Allergan. The institution of Dr. Vaught has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurelis. The institution of Dr. Vaught has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Teva. Dr. Vaught has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi.

��ɫ����

��ɫ����

��ɫ��

��ɫ��